Stock Analiz

Veracyte, Inc. (VCYT) financials: revenue, earnings and cash flow

Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Veracyte’s revenue went from $65M in fiscal 2016 to $517M in fiscal 2025, growth of about 25.9% a year.

Net income in fiscal 2025 was $66M, a net margin of 12.8%; the highest of the period.

Over the twelve months to September 30, 2026, revenue was $582M and net income $127M.

Free cash flow was $127M in fiscal 2025 and positive in 3 of the 10 years shown.

The diluted share count rose 179% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2016: $65M162017: $72M172018: $92M182019: $120M192020: $117M202021: $220M212022: $297M222023: $361M232024: $446M242025: $517M25$517M
Net income
2016: -$31M162017: -$31M172018: -$23M182019: -$13M192020: -$35M202021: -$76M212022: -$37M222023: -$74M232024: $24M242025: $66M25$66M
Free cash flow
2016: -$32M162017: -$26M172018: -$15M182019: -$6M192020: -$13M202021: -$37M212022: -$1M222023: $34M232024: $64M242025: $127M25$127M
EPS (diluted)
2016: $-1.09162017: $-0.91172018: $-0.62182019: $-0.27192020: $-0.66202021: $-1.11212022: $-0.51222023: $-1.02232024: $0.31242025: $0.8225$0.82

Income statement

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$582M$517M$446M$361M$297M$220M$117M$120M$92M$72M$65M
Gross profit$419M$363M$298M$230M$176M——$84M$59M$44M$40M
Operating income$99M$58M$16M-$86M-$41M-$82M-$35M-$15M-$22M-$27M-$29M
Net income$127M$66M$24M-$74M-$37M-$76M-$35M-$13M-$23M-$31M-$31M
EPS (diluted)$1.54$0.82$0.31$-1.02$-0.51$-1.11$-0.66$-0.27$-0.62$-0.91$-1.09
R&D$110M$71M$69M$57M$41M$30M$17M$15M$15M$14M$15M
Revenue growth—+16.0%+23.5%+21.8%+35.1%+86.9%−2.4%+30.8%+27.9%+10.5%+31.5%

Cash flow

Fiscal yearTTM2025202420232022202120202019201820172016
Operating cash flow$174M$136M$75M$44M$8M-$32M-$10M-$3M-$14M-$24M-$28M
Capital spending-$12M-$10M-$11M-$10M-$9M-$5M-$3M-$3M-$2M-$2M-$4M
Free cash flow$162M$127M$64M$34M-$1M-$37M-$13M-$6M-$15M-$26M-$32M
Dividends paid—$0$0$0$0$0$0$0$0$0$0
Buybacks———————————
Stock-based pay$52M$44M$36M$33M$27M$23M$13M$10M$6M$7M$6M

Balance sheet

Fiscal yearTTM2025202420232022202120202019201820172016
Cash—$363M$239M$216M$154M$173M$349M$159M$78M$34M$59M
Debt—$40M$51M$13M$15M$19M$12M$14M$25M$25M$25M
Equity—$1.3B$1.2B$1.0B$1.1B$1.1B$421M$239M$80M$37M$60M
Total assets—$1.4B$1.3B$1.1B$1.2B$1.2B$457M$275M$121M$79M$101M
Shares (diluted)83M81M78M73M72M68M53M46M37M34M29M

Margins and returns

Fiscal yearTTM2025202420232022202120202019201820172016
Gross margin72.0%70.1%66.9%63.6%59.2%——70.0%64.0%60.8%60.9%
Operating margin17.1%11.2%3.6%-23.8%-13.9%-37.3%-30.1%-12.6%-24.2%-36.9%-44.2%
Net margin21.8%12.8%5.4%-20.6%-12.3%-34.4%-29.7%-10.5%-25.0%-43.1%-48.2%
FCF margin27.8%24.5%14.3%9.5%-0.3%-16.9%-10.7%-5.0%-16.7%-35.7%-49.5%
ROIC—4.2%1.2%-7.9%-3.0%-6.8%-8.2%-6.0%-21.2%-42.7%-34.1%
ROE—5.1%2.1%-7.1%-3.4%-6.9%-8.3%-5.3%-28.8%-83.3%-52.6%

Frequently asked questions

What is Veracyte’s annual revenue?

$517M in fiscal 2025 and $582M over the twelve months to September 30, 2026.

How much profit does Veracyte make?

Net income was $66M in fiscal 2025 (net margin 12.8%).

Is Veracyte’s revenue growing?

Yes: revenue rose 16.0% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.